[1]Song Z, Wu Y, Yang J, et al. Progress in the treatment of advanced gastric cancer [J]. Tumour Biol, 2017, 39(7): 1010428317714626.
[2]Remiker AS,Palumbo JS.Mechanisms coupling thrombin to metastasis and tumorigenesis[J].Thromb Res,2018,164 Suppl 1:S29-S33.
[3]Repetto O, De Re V. Coagulation and fibrinolysis in gastric cancer [J]. Ann N Y Acad Sci, 2017, 1404(1): 27-48.
[4]Kwon OK, Kim SW, Chae HD, et al. Validation of the 7th AJCC/UICC staging system for gastric cancer and a proposal for a new TNM system based on a prognostic score: a retrospective multicenter study [J]. Ann Surg Treat Res, 2016, 91(6): 295-302.
[5]Sun RQ, Yang HF. The application of disseminated intravascular coagulation score in sepsis [J]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 2009, 21(8): 478-480.
[6]Refaai MA, Riley P, Mardovina T, et al. The clinical significance of fibrin monomers[J]. Thromb Haemost, 2018, 118(11): 1856-1866.
[7]Otten HM, Mathijssen J, ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon [J]. Arch Intern Med, 2004, 164(2): 190-194.
[8]Carroll BJ, Piazza G. Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test [J]? Vasc Med, 2018, 23(4): 388-399.
[9]郑青秀, 徐小小, 刘刚, 等. 补阳还五汤对气虚血瘀型肺癌患者血液高凝状态的影响[J].中国临床药理学与治疗学, 2018, 23(6): 694-699.
[10]Martín Guerra JM, Asenjo MM, Dueas Gutiérrez CJ, et al. Synchronous cardiopulmonary consequences of the hypercoagulable state associated with cancer [J]. Arch Bronconeumol, 2018, pii: S0300-2896(18)30328-4.
[11]De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms [J]. Crit Rev Oncol Hematol, 2004, 50(3): 187-196.
[12]Francis CW. Prevention of venous thromboembolism in hospitalized patients with cancer [J]. J Clin Oncol, 2009, 27(29): 4874-4880.
[13]王洛波, 王兵,丁语, 等. 利伐沙班和华法林治疗下肢深静脉血栓形成的疗效比较[J]. 医药导报, 2016, 35(10): 1089-1091.
[14]Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer[J]. J Clin Oncol, 2007, 25(34): 5490-5505.
[15]Remiker AS, Palumbo JS. Mechanisms coupling thrombin to metastasis and tumorigenesis[J]. Thromb Res, 2018, 164 Suppl 1: S29-S33.
[16]Smorenburg SM, Van Noorden CJ. The compex effects of heparins on cancer progression and metastasis in experimental studies [J]. Pharmacol Rev, 2001, 53(1): 932105
[17]Kragh M, Binderup L, Vig Hjarnaa PJ, et al. Non-anti-coagulant heparin Inhibits metastasis but not primary tumor growth [J]. Oncol Rep, 2005, 14 (1) : 992104.
[18]Yoshitomi Y, Nakanishi H, Kusano Y, et al. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemicallymodified heparin with reduced anticoagulant activity [J]. Cancer Lett, 2004, 207(2): 1652174
[19]Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS)[J]. J Clin Oncol, 2004, 22(10): 1944-1948.
[20]椰慧楠, 王哲, 汪忠淼. 低分子肝素对恶性肿瘤患者血液高凝状态以及生存率的影响[J]. 疑难病杂志, 2016, 15(3): 273-275,279. |